Physician
Oncology
Dr. John D. Hainsworth, MD
|
|
Give Review
John D. Hainsworth works in the field of Oncology. He went to Vanderbilt University School of Medicine. Dr. John D. Hainsworth has written publications. He has 101 publications published with PubMed. The lastest paper is: 'Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.'
Publications
- Sorafenib Plus Ixabepilone as First-Line Treatment of Metastatic HER2-Negative Breast Cancer: A Sarah Cannon Research Institute Phase I/II Trial.
- Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase...
- A phase II trial of ixabepilone and cyclophosphamide as neoadjuvant therapy for patients with HER2-negative breast cancer: correlation of pathologic complete response ...
- Poorly Differentiated Neoplasms of Unknown Primary Site: Diagnostic Usefulness of a Molecular Cancer Classifier Assay.
- Pazopanib and liposomal Doxorubicin in the treatment of patients with relapsed/refractory epithelial ovarian cancer: a phase ib study of the sarah cannon research inst...
- Phase I/II Study of the Combination of Panobinostat and Carfilzomib in Patients with Relapsed/Refractory Multiple Myeloma.
- Paclitaxel/carboplatin with or without belinostat as empiric first-line treatment for patients with carcinoma of unknown primary site: A randomized, phase 2 trial.
- Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: a randomized phase II study of th...
- Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial.
- Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Operable Breast Cancer: A Phase II Trial of the Sarah Cannon Research Institute.
- Biomarker Analyses from a Randomized, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab with or without Erlotinib as Maintenance Therapy for the Treatment of ...
- Phase I/II Trial of Orteronel (TAK-700)--an Investigational 17,20-Lyase Inhibitor--in Patients with Metastatic Castration-Resistant Prostate Cancer.
- Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
- Rituximab With or Without Bevacizumab for the Treatment of Patients With Relapsed Follicular Lymphoma.
- Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
- Evolving understanding and management of poorly differentiated neuroendocrine tumors.
- ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With B...
- Everolimus in combination with paclitaxel and carboplatin in patients with metastatic melanoma: a phase II trial of the Sarah Cannon Research Institute Oncology Resear...
- Carcinoma of unknown primary with gastrointestinal profile: immunohistochemistry and survival data for this favorable subset.
- Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II ...
- High-Dose Bevacizumab in the Treatment of Patients With Advanced Clear Cell Renal Carcinoma: A Phase II Trial of the Sarah Cannon Oncology Research Consortium.
- Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard Pathology.
- Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium.
- Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: A Sarah Cannon Research Institute phase II...
- Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective ...
- Phase II trial of ixabepilone and carboplatin with or without bevacizumab in patients with previously untreated advanced non-small-cell lung cancer.
- Phase II study of maintenance sunitinib following irinotecan and carboplatin as first-line treatment for patients with extensive-stage small-cell lung cancer.
- A Phase II Trial of Preoperative Concurrent Chemotherapy/Radiation Therapy Plus Bevacizumab/Erlotinib in the Treatment of Localized Esophageal Cancer.
- Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First-Line Treatment for Patients With Glioblastoma.
- A Retrospective Study of Treatment Outcomes in Patients with Carcinoma of Unknown Primary Site and a Colorectal Cancer Molecular Profile.
- A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced N...
- Combined Modality Treatment With Chemotherapy, Radiation Therapy, Bevacizumab, and Erlotinib in Patients With Locally Advanced Squamous Carcinoma of the Head and Neck:...
- Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer.
- Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer.
- Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology...
- A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine.
- Randomized, Double-Blind, Placebo-Controlled, Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer.
- Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
- A Phase II Study of Higher Dose Weekly Topotecan in Relapsed Small-Cell Lung Cancer.
- Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor...
- A pilot study of adjuvant Doxorubicin and cyclophosphamide followed by Paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer.
- BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/paclitaxel as first-line treatment for patients with advanced, previously untre...
- A phase II trial of dose-dense neoadjuvant gemcitabine, epirubicin, and albumin-bound paclitaxel with pegfilgrastim in the treatment of patients with locally advanced ...
- A phase II, open-label, randomized study to assess the efficacy and safety of AZD6244 (ARRY-142886) versus pemetrexed in patients with non-small cell lung cancer who h...
- Bevacizumab and everolimus in the treatment of patients with metastatic melanoma: a phase 2 trial of the Sarah Cannon Oncology Research Consortium.
- Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme.
- Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer.
- Phase III multicenter trial of doxorubicin plus cyclophosphamide followed by paclitaxel compared with doxorubicin plus paclitaxel followed by weekly paclitaxel as adju...
- Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
- Phase II trial of vinflunine in relapsed small cell lung cancer.
- A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer.
- A phase II trial of neoadjuvant gemcitabine, epirubicin, and docetaxel as primary treatment of patients with locally advanced or inflammatory breast cancer.
- Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology ...
- Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer.
- Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma.
- Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal...
- Cancer of unknown primary site.
- Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab.
- Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III ...
- Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction.
- Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site.
- Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer.
- A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer.
- Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer.
- Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
- Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a pha...
- Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head an...
- Hematologic response to three alternative dosing schedules of azacitidine in patients with Myelodysplastic syndromes.
- Follicular lymphoma in the United States: first report of the national LymphoCare study.
- Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer.
- Neuroendocrine carcinoma of unknown primary site.
- Treatment for patients with unknown primary cancer and favorable prognostic factors.
- Introduction: unknown primary cancer.
- High-dose etoposide: from phase I to a component of curative therapy.
- A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer.
- Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation.
- Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network.
- Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TR...
- Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
- A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high...
- Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocyt...
- Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial.
- Weekly docetaxel versus docetaxel/gemcitabine in the treatment of elderly or poor performance status patients with advanced nonsmall cell lung cancer: a randomized pha...
- Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Netw...
- Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
- Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation st...
- Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study.
- Docetaxel and epirubicin as first-line treatment for patients with metastatic breast cancer: a Minnie Pearl Cancer Research Network Phase II trial.
- Phase II multicenter study of arsenic trioxide in patients with Myelodysplastic syndromes.
- Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II tri...
- A Phase I trial of protracted oral fixed-dose temozolomide.
- Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
- Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Netwo...
- Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective...
- Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab.
- Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
- Paclitaxel, carboplatin, and gemcitabine in the treatment of patients with advanced transitional cell carcinoma of the urothelium.
- Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
- A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer.
- Paclitaxel, carboplatin, and oral etoposide as initial treatment for advanced ovarian carcinoma: a Minnie Pearl Cancer Research Network phase II trial.
Schools
Vanderbilt University School Of Medicine
Vanderbilt University Hospital
Conditions Treated
- Myelodysplastic Syndromes
- Myeloproliferative Disorders
- Neutropenia
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
- Cigna HMO
- Great West Healthcare-Cigna PPO
- Medicare MCR
Education
-
Vanderbilt University -
Vanderbilt University School of Medicine
Helpful Reviews
Similar Doctors
|
|
Dr. William C. Penley, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. Michel E. Kuzur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kristin K. Ancell, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Leora Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Anuradha Chakravarthy, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Kenneth R. Hande, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Vicki L. Keedy, MD
This Doctor is OpenDoctor Recommended.
|